EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieVergleichsstudie

Efficacy of nivolumab + ipilimumab ± chemotherapy versus pembrolizumab + chemotherapy in patients with PD-L1-negative non-small cell lung cancer (START001 PART-B): a multicenter retrospective observational study

Yutaro Nagano, Mamoru Takahashi, Toshiyuki Sumi, Keiki Yokoo, Tatsuru Ishikawa, Osamu Honjo, Sayaka Kudo, Shun Kondo, Yusuke Tanaka, Makoto Shioya, Midori Hashimoto, Mitsuo Otsuka und 9 weitere

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyaf073 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Yutaro Nagano und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Otaru General Hospital, 1-1-1 Wakamatsu, Otaru, Hokkaido 047-0017, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Nivolumab, Antibodies, Monoclonal, Humanized, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Programmed death ligand 1 (PD-L1) serves as a crucial biomarker for predicting the efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer (NSCLC). This study aimed to identify the most suitable first-line treatment regimen for patients with PD-L1 expression <1% (PD-L1-negative) NSCLC by comparing nivolumab plus ipilimumab (NI), NI combined with chemotherapy (NICT), and pembrolizumab and chemotherapy (PCT).

Methods

We analyzed data from 141 patients with PD-L1-negative NSCLC treated with NI, NICT, or PCT at 14 Japanese institutions between December 2020 and November 2022. Propensity score analysis was employed to minimize selection bias, and Kaplan–Meier analysis and Cox proportional hazards regression were used to evaluate progression-free survival (PFS) and overall survival (OS).

Results

Neither NI nor NICT demonstrated superior PFS or OS than PCT. Subgroup analyses revealed no significant differences between treatment groups across age, histological subtypes, or clinical features. Results from propensity score matching and inverse probability of treatment weighting were consistent with those observed in the overall cohort. Moreover, safety profiles showed that PCT was associated with the lowest rates of treatment discontinuation and immune-related adverse events requiring systemic corticosteroid therapy.

Conclusions

In patients with PD-L1-negative NSCLC, the efficacy of NI and NICT was not superior to that of PCT. Thus, we concluded that PCT could be a favorable treatment option for this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungNivolumabAntibodies, Monoclonal, HumanizedLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsIpilimumabHumansMaleFemaleRetrospective StudiesMiddle AgedAgedB7-H1 AntigenAdultAged, 80 and over

Stichwörter der Autor:innen

chemotherapyipilimumabnivolumabnon-small cell lung cancerpembrolizumab

Substanzen

NivolumabpembrolizumabAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, humanIpilimumab

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Otaru General Hospital, 1-1-1 Wakamatsu, Otaru, Hokkaido 047-0017, Japan.
  • Department of Respiratory Medicine, Hakodate Municipal Hospital, 1-10-1 Minato-cho, Hakodate, Hokkaido 041-0821, Japan.
  • Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, 291 Minami 1-jo Nishi 16-chome, Chuo-ku, Sapporo, Hokkaido 060-8543, Japan.
  • Department of Respiratory Medicine, Hakodate Goryoukaku Hospital, 38-3 Goryokaku-cho, Hakodate, Hokkaido 041-8611, Japan.
  • Department of Respiratory Medicine, Teine Keijinkai Hospital, 1-40 Maeda 1-jo 12-chome, Teine-ku, Sapporo, Hokkaido 006-0811, Japan.
  • Department of Respiratory Medicine, Sapporo Minami-Sanjo Hospital, 4-2 Minami 3-jo Nishi 6-chome, Chuo-ku, Sapporo, Hokkaido 060-0063, Japan.

Zitieren

APA

Nagano, Y., Takahashi, M., Sumi, T., Yokoo, K., Ishikawa, T., Honjo, O., Kudo, S., Kondo, S., Tanaka, Y., Shioya, M., Hashimoto, M., Otsuka, M., Sudo, Y., Yanagi, M., Yabe, H., Nishikiori, H., Yamazoe, M., Asai, Y., Fukataki, Y., …, & Chiba, H. (2025). Efficacy of nivolumab + ipilimumab ± chemotherapy versus pembrolizumab + chemotherapy in patients with PD-L1-negative non-small cell lung cancer (START001 PART-B): a multicenter retrospective observational study. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf073

Vancouver

Nagano Y, Takahashi M, Sumi T, Yokoo K, Ishikawa T, Honjo O, et al. Efficacy of nivolumab + ipilimumab ± chemotherapy versus pembrolizumab + chemotherapy in patients with PD-L1-negative non-small cell lung cancer (START001 PART-B): a multicenter retrospective observational study. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf073

BibTeX
@article{Nagano2025,
  author = {Nagano, Yutaro and Takahashi, Mamoru and Sumi, Toshiyuki and Yokoo, Keiki and Ishikawa, Tatsuru and Honjo, Osamu and Kudo, Sayaka and Kondo, Shun and Tanaka, Yusuke and Shioya, Makoto and Hashimoto, Midori and Otsuka, Mitsuo and Sudo, Yuta and Yanagi, Masahiro and Yabe, Hayato and Nishikiori, Hirotaka and Yamazoe, Masami and Asai, Yuichiro and Fukataki, Yasuko and Hinotsu, Shiro and Chiba, Hirofumi},
  title = {Efficacy of nivolumab + ipilimumab ± chemotherapy versus pembrolizumab + chemotherapy in patients with PD-L1-negative non-small cell lung cancer (START001 PART-B): a multicenter retrospective observational study},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyaf073}
}
Kostenlos starten →